跳转至内容
Merck

SML0476

Sigma-Aldrich

Rabeprazole sodium

≥98% (HPLC)

别名:

2-([4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole, Pariprazole

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H20N3O3S · Na
分子量:
381.42
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to beige

溶解度

H2O: 10 mg/mL (clear solution)

運輸包裝

wet ice

儲存溫度

−20°C

SMILES 字串

[Na+].COCCCOc1ccnc(CS(=O)c2nc3ccccc3[n-]2)c1C

InChI

1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1

InChI 密鑰

KRCQSTCYZUOBHN-UHFFFAOYSA-N

基因資訊

正在寻找类似产品? 访问 产品对比指南

應用

Rabeprazole sodium has been used as a proton pump inhibitor (PPI) to study its effects on spontaneous uterine contractile activity in pregnant women.

生化/生理作用

Rabeprazole sodium is gastric proton pump inhibitor. It suppresses the production of acid in the stomach by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Rabeprazole sodium has been used clinically to treat acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevent gastroinetestinal bleeds associated with NSAID use.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Aquatic Chronic 4

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Increased gap density predicts weakness of the epithelial barrier in vivo by confocal laser endomicroscopy in indomethacin-induced enteropathy.
Shi S, Wang H, Gao H, et al.
Digestive Diseases and Sciences, 59(7), 1398-1405 (2014)
Hyun Jeong Lee et al.
The Journal of infectious diseases, 208(7), 1123-1130 (2013-06-27)
Clarithromycin-resistant Helicobacter pylori is associated with point mutations in the 23S ribosomal RNA (rRNA) gene. A total of 1232 patients participated and were divided into 2 control groups and 1 case group. Patients in the APC control group, which consisted
Tarek A Ahmed et al.
Life sciences, 110(1), 35-43 (2014-07-06)
First; to develop rabeprazole (RP)-alginate core coated chitosan nanoparticles (NP) utilizing water in oil (W/O) nanoemulsion technique. Second; formulation of transdermal patches loaded RP-NP that avoid drug peroral acid sensitivity and first pass effect. The influence of six factors on

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门